Triple-negative breast cancers (TNBCs) account for roughly 10 to 15 percent of all breast cancers. They disproportionately affect African American and Hispanic women, young women, and women with mutations on the BRCA1 gene.
TNBCs are notoriously aggressive and difficult to treat, due in part to the limited treatment options that exist outside of chemotherapy.
However, according to a new study, two drugs that have been used to treat other diseases for decades might help improve outcomes in people with TNBCs.
Those two drugs are a diabetes medication called metformin and a drug for rare disorders called heme.
Researchers want to know, if used together, whether they can provide effective treatment for people with TNBC.
Another drug, heme is marketed under the brand name Panhematin. It’s used to treat porphyrias, a group of rare disorders that can affect the skin or nervous system.
Rosner’s research team used heme to inhibit the production of a protein known as BACH1, which tends to be highly expressed in TNBCs.
Metformin has anti-cancer effects
Metformin is the first-line treatment for type 2 diabetes and one of the most commonly prescribed medications in the United States.
In recent studies, it’s also been shown to have anti-cancer effects that may suppress the growth of tumors and induce the death of cancer cells in people taking the medication.
However, some cancer cells are more sensitive to metformin than others.
“Because metformin, a drug used by diabetics, has been associated with decreased cancer risk, there are a number of clinical trials currently ongoing [that are] testing its role in cancer treatment,” Marsha Rosner, PhD, the senior author of the study and a professor in the Ben May Department for Cancer Research at the University of Chicago, told Healthline.
She said currently there is no marker to predict who might benefit from metformin treatment or who might be resistant.
That’s where her team’s research findings on another drug, heme, might prove useful.
Fighting triple-negative breast cancer
According to Dr. Alice Police, the regional director of breast surgery in Westchester County at Northwell Health Cancer Institute, these initial research findings are promising.
“It’s really amazing and potentially groundbreaking because it’s two medications that people all over the world take all the time.
So we already know that metformin and Panhematin have excellent safety profiles,” she continued, “and are not as full of side effects as most chemotherapy and some of the harsher immunotherapy drugs,” Police said.
Several targeted therapies have been developed to treat other types of breast cancer, including HER2-positive breast cancers, estrogen-positive breast cancers, and progesterone-positive breast cancers.
However, those targeted therapies don’t work for TNBCs.
Instead, most people with TNBCs rely on toxic regimens of chemotherapy.
“The chemotherapy that they’re getting is really strong cytotoxic chemotherapy that has significant side effects and not great safety profiles.
So the idea that there’s two medications with a very low toxicity profile that might have an effect on this horrible disease is just wonderful,” she added.